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Abstract
Background: Bacterial meningitis is associated with significant morbidity and mortality despite advances in medical
care. The main objective of this study was to assess the association of adjunctive dexamethasone treatment with
discharge outcome of patients treated as bacterial meningitis in low income setting.
Methods: A retrospective study was conducted at four teaching hospitals across Ethiopia. Patients of age 14 years and
older treated as cases of bacterial meningitis between January 1, 2011 and April 30, 2015 were included in this study.
Information regarding sociodemographic data, clinical presentations, laboratory data, treatments given and status at
hospital discharge were retrieved from patients’ medical records using a structured questionnaire. Predefined outcome
variables at discharge were analysed using descriptive statistics. Multivariable logistic regression was used to identify
factors independently associated with poor outcome.
Results: A total of 425 patients treated with the presumptive clinical diagnosis of bacterial meningitis were included in
this study (lumbar puncture done in 56 %; only 19 % had CSF findings compatible with bacterial meningitis, and only
3 % had proven etiology). The overall in hospital mortality rate was 20.2 %. Impaired consciousness, aspiration
pneumonia, and cranial nerve palsy at admission were independently associated with increased mortality.
Adjuvant dexamethasone, which was used in 50.4 % of patients, was associated with increased in-hospital mortality
(AOR = 3.38; 95 % CI 1.87–6.12, p < 0.001) and low Glasgow outcome scale (GOS) at discharge (AOR = 4.46 (95 % CI 1.
98–10.08). This association between dexamethasone and unfavorable outcome was found to be more pronounced in
suspected but unproven cases and in those without CSF alterations compatible with bacterial meningitis.
Conclusion: Most patients treated for suspected bacterial meningitis did not receive proper diagnostic
workup. Adjuvant dexamethasone use in clinically suspected but unproven cases of bacterial meningitis was
associated with an increased mortality and poor discharge GOS. These findings show that there are potential
deleterious effects in unconfirmed cases in this setting. Physicians practising under such circumstances should thus
abide with the current recommendation and defer the use of adjuvant corticosteroid in suspected cases of
bacterial meningitis.
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Background
Bacterial meningitis is a serious infection of the central
nervous system that can progress rapidly and result in
death or permanent debilitation [1]. It is associated with
a high fatality rate despite advances in medical care [2]
and a significant proportion of survivors suffer from
long term neurologic sequelae [3]. Most of the cases of
acute bacterial meningitis (ABM) occur in low income
countries [4] where case fatality rates are higher than in
countries with a high standard of medical care [5, 6].
The duration of disease [7], age [8], and immune status
of the patient [9–11], timing of antibiotic initiation [12, 13],
and type of microorganism [14, 15] were found to be im-
portant factors in determining the outcome of ABM. Sig-
nificant controllable factors known to improve survival and
neurologic recovery are rapid diagnosis and an early treat-
ment [12, 16], both of which are difficult to achieve when
laboratory support and treatment options are limited [4].
Corticosteroid as adjunctive treatment of ABM is one
of the most thoroughly studied and widely discussed
controversial issues in recent years [17–21]. Yet, its
benefit in mortality and morbidity reduction is far from
being settled [20–23]. The existing evidences indicate
that the efficacy of dexamethasone varies with etiologic
agents [24, 25], clinical circumstances and regions of the
world [19, 24–27]. The current adult recommendations
limit its use to pneumococcal meningitis in high income
countries [24, 25]. Furthermore, the few studies from the
developing world did not find any benefits of cortico-
steroid on mortality and neurologic sequelae [28–30].
We recently analysed the characteristics of 425 pa-
tients who were treated and discharged with the pre-
sumed diagnosis of bacterial meningitis. One of the
main findings was that CSF analysis was done in only
56 % of these patients and the diagnosis could be proven
by detection of a causative pathogen in as little as 3.3 %
of patients [31]. Now we aimed to assess treatment out-
comes and factors associated with poor outcome in
these patients. We especially aimed to investigate the ef-
fect of adjunctive dexamethasone treatment on the out-
come of patients treated for suspected ABM in the four
study centres in Ethiopia.
Methods
Settings
Ethiopia is a country located in East Africa with an esti-
mated population of 87,952, 000 as of July 2014 [32].
This study was conducted at four teaching hospitals in
Ethiopia – Jimma University Specialized Hospital, Hawassa
University Referral Teaching Hospital, University of
Gondar Hospital and Arba Minch Hospital. The first
three are full-fledged university hospitals serving as
referral hospitals. Arba Minch hospital is a general
hospital affiliated with Arba Minch University’s med-
ical school. All of these hospitals are located in the
eastern end of meningitis belt of Africa in different
regions of Ethiopia– Northwest (Gondar), southwest
(Jimma), south (Arba Minch) and southcentral
(Hawassa). The overall catchment population of the
four hospitals is nearly 25 million – over a quarter of
the Ethiopian population.
Design
A hospital based retrospective cohort study was conducted
using medical record review of patients treated as cases of
bacterial meningitis at the four hospitals during the period
of 1 January, 2011 to 30 April, 2015. Clinical characteristics
of the patients were recently published [31].
Study participants
Patients included in the study were those of age 14 years
and older treated with a presumptive diagnosis of bac-
terial meningitis and who had complete medical records
regarding issues related to diagnosis, treatment and out-
come of ABM. Patients whose antibiotic treatment was
discontinued before ward admission because of con-
firmed alternative diagnosis and those with incomplete
clinical records were excluded.
Cases treated as bacterial meningitis were categorized
based on the 2003 World Health Organization case def-
inition used in WHO-recommended surveillance stan-
dards for surveillance of selected vaccine-preventable
diseases [33]. These categories are:
Suspected unproven cases of bacterial meningitis –
Cases with acute onset (≤7 days) of fever (axillary
temperature of ≥38.0 °C) PLUS any of: neck stiffness
and altered consciousness PLUS no other alternative
diagnosis PLUS no or incomplete CSF analysis.
Possible bacterial meningitis – Cases with clinical signs
as described for “suspected unproven ABM” PLUS CSF
examination showing at least one of the following
three – (1) turbid appearance (2) pleocytosis (>100
white cells/mm3) (3) pleocytosis (10–100 white cells/mm3)
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AND either an elevated protein (>100 mg/dl) or decreased
CSF to serum glucose ratio (<40 %).
Confirmed (proven) bacterial meningitis – Cases with
detected microorganisms by culture, gram stain or
agglutination test from CSF specimen.
Non-cases (bacterial meningitis less likely) – Cases not
fulfilling any of the above criteria and/or those with
evidences suggesting other diagnoses.
Data collection procedure
Patients treated as cases of ABM were identified using the
data from inpatient registration books of medical wards at
each hospital. Their medical records were then retrieved
from the archives to be reviewed according to a structured
questionnaire prepared for the study (Additional file 1).
The information gathered included socio-demographic
profiles, clinical conditions at presentation, type of anti-
biotic treatment, adjunctive dexamethasone treatment,
clinical course in the hospital, and discharge conditions
(death and neurologic sequelae). Glasgow Outcome Scale
(GOS) was interpreted from the discharge note (see
below).
Definitions of outcome variables
Focal neurologic deficit (FND) – refers to (1) unilateral
extremity weakness [monoparesis or hemiparesis] (2)
unilateral hypaesthesia (3) localized cranial nerve palsies
(III, IV and VII).
Glasgow Outcome Scale (GOS) – was the interpret-
ation of treating physician’s documentation of the patient
status at discharge. 1 = if death was documented; 2 = if pa-
tient was in ‘coma’ or ‘unresponsiveness’ at leaving hos-
pital; 3 = if document included ‘some improvement’ and
any of ‘hemiplegia’, ‘paraparesis’, or ‘major disability’; 4 = if
document included ‘improved’ with minor sequelae such
as ‘facial palsy’ or ‘decreased hearing capacity’; 5 = if docu-
ment included ‘full recovery’ or ‘discharge with complete
improvement’.
Level of consciousness – was stated using Glasgow
Coma Scale (GCS) which ranges from score of 3 to 15.
Patients with score of 15 were considered as fully con-
scious; 9–14 as impaired consciousness and as coma for
scores between 3 and 8.
Data processing, analysis and interpretation
The data was checked for completeness and consistency. It
was then entered to EpiData version 3.1 and was later trans-
ferred to SPSS® (IBM Corporation) version 20 for analysis.
Bivariable analysis was done to identify association be-
tween dependent and independent variables. All inde-
pendent variables with p < 0.25 in bivariate analysis were
entered for multivariable analysis. Forward logistic regres-
sion analysis was done to identify the best fit model. Inde-
pendent predictors were analysed for three outcome
variables – death, Glasgow outcome scale and neurologic
sequelae at discharge from the hospital. P-values of
<0.05 were used as level of statistical significance.
Results
Background clinical characteristics
Complete medical records were available for 425 pa-
tients treated as bacterial meningitis. The main clinical
characteristics of the patients have been previously de-
scribed in detail [31]. Briefly, the mean age at presenta-
tion was 32 ± 15.7 years (range 14 to 85); 52.7 % of them
were men. Only about 30 % (127 patients) presented
within 2 days of symptom onset. Fever and headache
were major presenting symptoms. On presentation, 213
(50.1 %) of patients had impaired consciousness and 33
(7.8 %) had focal neurologic deficits.
HIV infection was detected in 23 (5.4 %) patients,
however, only 349 (82.1 %) were tested for it. Forty-four
(10.4 %) patients had additional diagnosis of pneumonia,
all of which were attributed to aspiration. Lumbar punc-
ture was done for 236 (55.5 %) of patients; 220 (93.2 %)
of them had microscopic examination of Gram-stained
CSF specimen. Leukocyte count was done for 180
(76.3 %) of these patients but only 58.1 % had analysis
for both protein and glucose. Culture was done for only
61(25.8 %) of these cases. Only 14 (3.3 %) of them had a
confirmed etiology and classified as “proven ABM”; 82
(19.3 %) belonged to the category of possible ABM.
About 46 % (196 patients) were classified as suspected
unproven cases. In all cases in this category, CSF was ei-
ther only partially analysed or not collected at all. The
rest 133 (31.3 %) did not fulfil clinical or laboratory
based definitions of ABM [31].
Antimeningeal dose of intravenous ceftriaxone (4 g/day)
alone or in combination with other antibiotics was used in
all patients except for one, who was given a combination
of benzyl penicillin and chloramphenicol. Intravenous
metronidazole was given to 44 (10.4 %) patients for sus-
pected aspiration pneumonia. Adjunctive dexamethasone
treatment was given to 214 (50.4 %) patients [31].
Discharge outcome
One hundred fifty-six (36.7 %) were discharged with un-
favorable outcome (GOS = 1–4); 86 patients (20.2 %)
died in the hospital. The median time from hospital ad-
mission to death was 3 days; 55.8 % of the deaths oc-
curred in the first 4 days of admission.
Of those who left the hospital alive (339), 277 (81.7 %)
were discharged and 57 (16.8 %) left against medical ad-
vice (LAMA). Among surviving patients, 70 (20.6 %)
had unfavourable GOS (2 to 4); 38 (11.2 %) had docu-
mented neurologic sequelae.
The average length of hospital stay (LOS) for discharged
patients was 11.0 days (SD = 6.6). Those who left against
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medical advice had a LOS of 6.1 days (SD = 3.7) and 52.6 %
of them left in the first 4 days of admission (Table 1).
Factors associated with poor outcome
Glasgow outcome scale (GOS) – by dichotomizing GOS
into favorable (GOS = 5) and unfavorable (GOS =1 to 4)
outcome, we found that admission GCS (AOR= 0.77; 95 %
CI = 0.66–0.89) and dexamethasone treatment (AOR =
4.46; 95 % CI 1.98–10.08) were independently associated
with unfavorable outcome. Note that GCS had reverse as-
sociation with poor outcome; every increment from lowest
of 3 to 15 resulted in improvement of outcome by 23 %.
Fifty-two (12.2 %) of patients were additionally treated
with presumptive diagnosis of tuberculous meningitis
(TBM). These groups of patients had unfavourable
outcome at discharge as compared to other groups
(AOR = 2.78; 95 % CI 1.06–7.30).
In hospital death – Admission Glasgow coma scale,
presence of pneumonia and cranial nerve palsy during
hospitalization were patient related factors independ-
ently associated with increased mortality. Accordingly,
every drop of GCS from 15 was associated with increment
of mortality by 21 % (AOR= 0.79; 95 % CI = 0.73–0.85).
On the other hand, adjunctive dexamethasone therapy
was found to be associated with over 3 times increment of
mortality (AOR = 3.38; 95 % CI = 1.87–6.12) (Table 2).
However, no association was seen between increased mor-
tality and other conventional risk factors such as duration
of illness, age of the patient and HIV infection.
Neurologic sequelae – Focal neurologic deficits (AOR
= 3.33; 95 % CI 1.31–8.50), seizures (AOR = 2.20; 95 %
CI 1.03–4.67) and a low level of consciousness (AOR =
2.65; 95 % 1.21–5.81) at admission were associated with
the occurrence of neurologic sequelae at discharge. This
analysis showed also that a delay of one day from symp-
tom onset to hospital presentation was associated with
9 % increment in risk of neurologic sequelae (AOR =
1.09; 95 % CI 1.01–1.16) (Table 2).
As described above, 15 % of patients left hospital
against medical advice or referred for better care. Separ-
ate analysis was done to assess if these patients differed
clinically from discharged patients. Accordingly, they
were found to have lower GOS, lower GCS and higher
proportion of neurologic sequelae when leaving the hos-
pital (Table 3).
Table 1 Outcome at leaving hospital in patients treated as







Status at leaving hospital (N = 425), n (%)
Discharged 277 (65.2) 125 (58.4) 152 (72.0)
Left against medical
advice
57 (13.4) 26 (12.1) 31 (14.7)
Referred 5 (1.2) 1 (0.5) 4 (1.9)
Died 86 (20.2) 62 (29.0) 24 (11.4)
Discharge condition of survivors (N = 339), n (%)
Complete recovery 230 (67.9) 98 (64.5) 132 (70.6)
Some improvement 78 (23.0) 41 (27.0) 37 (19.8)
The same as admission 31 (9.1) 13 (8.6) 18 (9.6)
GOS (N = 425), n (%)
1 86 (20.2) 62 (29.0) 24 (11.4)
2 22 (5.2) 9 (4.2) 13 (6.2)
3 9 (2.1) 5 (2.3) 4 (1.9)
4 39 (9.2) 26 (12.1) 13 (6.2)
5 269 (63.3) 112 (52.3) 157 (74.4)
Neurologic sequelae (N = 38 a), n (%)
Low GCS 18 (47.4) 5 (27.8) 13 (59.1)
Hemiparesis 8 (21.1) 4 (22.2) 4 (18.2)
Seizure 9 (23.7) 6 (33.3) 3 (13.6)
Paraparesis 3 (7.9) 3 (16.7) 0
Cranial nerve palsy 2 (5.3) 0 2 (9.1)
Length of hospital stay in days, mean (SD)
Total 8.9 (6.4) 8.8 (7.0) 9 (5.8)




GOS Glasgow outcome scale, LAMA left against medical advice
a2 Patients had multiple complications
Table 2 Factors independently associated with poor outcomes
at leaving hospital in patients treated as bacterial meningitis at
teaching hospitals in Ethiopia, 2011–2015
Variable AOR 95 % CI P-value
Death
Level of consciousness at presentation
(for a point increase in GCS)
0.79 0.73–0.85 <0.001
Dexamethasone treatment 3.38 1.87–6.12 <0.001
Aspiration pneumonia at presentation 2.97 1.36–6.41 0.006
Cranial nerve palsy at presentation 4.73 1.45–15.50 0.010
Unfavorable outcome (GOS = 1–4)
Level of consciousness at presentation
(for a point increase in GCS)
0.77 0.66–0.89 <0.001
Dexamethasone treatment 4.46 1.98–10.08 <0.001
TB suspected cases 2.78 1.06–7.30 0.038
Neurologic sequelae
Focal neurologic deficit at presentation 3.33 1.31–8.50 0.012
Seizure at presentation 2.20 1.03–4.67 0.041
Duration of illness before presentation 1.09 1.01–1.16 0.020
Impaired consciousness (GCS < 15) 2.65 1.21–5.81 0.015
This table presents output of Forward logistic regression analysis
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Dexamethasone treatment and its association with
discharge outcomes
Chi-square test showed that dexamethasone was used more
often in confirmed and probable cases of bacterial meningi-
tis, those with turbid CSF and organism detected by Gram
staining. On the other hand, it was found to be prescribed
less often in HIV-positive patients as compared to non-
HIV cases. There was also a clear difference in the pattern
of dexamethasone treatment between hospitals ranging
from 23.5 % at Hawassa to 73.9 % at Gondar (Table 4).
Dexamethasone treatment was associated with an in-
crease of the in-hospital mortality, COR = 3.18 (95 % CI
1.90–5.33); p < 0.001 and low GOS at discharge, COR =
2.65 (95 % CI 1.76–3.99); P < 0.001. However, there was no
association with neurologic sequelae at discharge (Fig. 1).
As depicted on Table 2, dexamethasone was found to be
one of the factors independently associated with poor out-
come on multivariable analysis with the best-fit model.
When further analysis was performed controlling for all
potential confounders on multiple logistic regressions with
forced entry, this association persisted. For instance, the
odds of having low GOS at discharge was nearly 4 times,
AOR = 3.94 (95 % CI 1.63–9.53; P = 0.002) and its associ-
ation with in hospital death was also nearly as much,
AOR = 3.60 (1.97–6.60; P < 0.001).
Controlling for these individual variables also revealed
similar finding as shown on Table 5.
Dexamethasone and mortality – This association did
not differ between older and younger patients, whether a
patient had delayed presentation or not, and whether a
patient took prior antimicrobial treatment or not. How-
ever, this association faded in HIV infected patients,
those with neurologic deficit on presentation, those with
abnormal CSF findings and TB suspected cases.
Dexamethasone and low GOS – Age of the patient,
presence or absence of HIV infection, and prior anti-
biotic treatment did not change the nature of this associ-
ation. On the other hand, the association disappeared in
TB suspected cases, those with confirmed ABM and
neurologic deficit on presentation.
In summary, adjunctive dexamethasone treatment was
associated with poor outcome in most of the sub-
groups. However, this was not the case in patients with a
diagnosis of bacterial meningitis that was microbiologic-
ally proven or supported by CSF findings (those with
turbid CSF, proven BM and probable cases of BM), and
Table 3 Difference in secondary outcome variables between discharged patients and those who left the hospital against medical
advice or were referred to other centres, in patients treated as bacterial meningitis at teaching hospitals in Ethiopia, 2011–2015
Discharge
outcome
GOS, N (%) Neurologic sequelae, N (%) Impaired GCS, N (%)
2 3 4 5 P Yes No P Yes No P
LAMA/referred 21 (33.9) 6 (9.7) 20 (32.3) 15 (24.2) <0.001 16 (25.8) 46 (74.2) <0.001 13 (21.0) 49 (79.0) <0.001
Discharged 1 (0.4) 3 (1.1) 19 (6.9) 254 (91.7) 18 (6.5) 259 (93.5) 2 (0.7) 275 (99.3)
Table 4 Comparison of background characteristics by
dexamethasone treatment of patients treated as bacterial
meningitis in Ethiopia, 2011–2015
Characteristics Dexamethasone No dexamethasone P value
Mean age, year (SD) 30.1 (15.0) 33.9 (16.2) 0.116
Duration of illness,
days (SD)
5.2 (4.3) 5.0 (4.3) 0.683
Diagnosis of meningitis
Confirmed 12 (85.7) 2 (14.3) 0.001*
Probable 51 (62.2) 31 (37.8)
Suspected 84 (42.9) 112 (57.1)
Non-cases 67 (50.4) 66 (49.6)
Prior antibiotic treatment
Yes 45 (43.3) 59 (56.7) 0.096
No 169 (52.6) 152 (47.4)
Impairment of consciousness
Yes 102 (52.0) 94 (48) 0.52
No 112 (48.9) 117 (51.1)
Focal neurologic deficit
Yes 22 (66.7) 11 (33.3) 0.051
No 192 (49.0) 200 (51.0)
CSF appearance
Turbid 37 (64.9) 20 (35.1) <0.001*
Normal 68 (38.2) 110 (61.8)
Detection of organism by Gram stain
Yes 11 (84.6) 2 (15.4) 0.003*
No 89 ((43.0) 118 (57.0)
HIV status
Positive 7 (30.4) 16 (69.6) 0.048*
Negative 207 (51.6) 194 (48.4)
Hospital
Jimma 52 (42.6) 70 (57.4) <0.001
Gondar 24 (26.1) 68 (73.9)
Hawassa 65 (76.5) 20 (23.5)
Arba Minch 73 (57.9) 53 (42.1)
*statistically significant
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in those suspected to have TBM. In these cases, dexa-
methasone therapy was not associated with any positive
or negative discharge outcomes (Table 5).
The only one instance where dexamethasone was asso-
ciated with positive outcome is decreased discharge
neurologic sequelae in patients who had impaired
consciousness at presentation, AOR = 0.42 (95 % CI
0.19–0.94; P = 0.033).
Discussion
Our study revealed that patients treated for clinically
suspected ABM in teaching hospitals in Ethiopia were
found to have a high mortality of 20 %. However, most
of these patients did not receive a proper diagnostic
workup and were treated only pragmatically [31]. Hence,
the reported mortality may not reflect the true burden
of the problem in the settings. Moreover, adjunctive
dexamethasone treatment in patients who did not re-
ceive proper CSF analysis or in whom CSF findings were
not compatible with acute bacterial meningitis was asso-
ciated with poor discharge outcomes.
The finding in our study may not reflect the real mor-
tality associated with ABM in the setting. This is because
the diagnosis of ABM in substantial fraction of the pa-
tients was unclear and it is likely that many of these pa-
tients suffered from diagnosis other than ABM [31].
Therefore, it is not possible to compare the data to other
studies in patients with proven acute bacterial meningi-
tis. It further explains why the mortality of 20 % is much
lower than in meningitis studies from other low income
countries like Malawi, where mortality reached 40 %
[5, 6]. This is also reflected in the documented short-
term neurologic sequela in survivors which was only
11.2 %, a rate that is lower than in most reports on the
outcome of ABM [3, 5, 6, 15, 34, 35].
As expected, impaired consciousness at admission was
associated with poor outcome. This may be due to the se-
verity of the illness as well as the occurrence of complica-
tions like aspiration pneumonia which on itself was
associated with a higher mortality. However, conventional
poor prognostic indicators like age, causative bacteria,
duration of illness, and HIV infection were not found to
be associated with adverse outcome. The study was not
able to detect an effect of these factors due to small num-
ber of confirmed cases and due to the fact that only the
outcome at leaving the hospital was assessed. The study
may also be underpowered to detect an association be-
cause of the small number of HIV cases. However, 17.9 %
of patients did not receive HIV test which might have
underestimated its real prevalence.
Adjuvant corticosteroid in management of bacterial
meningitis in low and middle income countries, and in
settings with high HIV prevalence in particular, has
never been proven beneficial [28–30]. To date, there is
no recommendation of its use in such settings. However,
physicians in settings with little evidence and diagnostic
facilities like Ethiopia have continued its use based on
recommendation for high income countries [36, 37].
The finding in our study, where dexamethasone was used
in half of the patients, is a testimony of scepticism towards
the current recommendation in low income countries.
As it highlighted on Table 5, dexamethasone use was
not associated with any positive or negative outcome in
those patients with confirmed or probable cases of bac-
terial meningitis. The lack of evidence for its benefit in
Ethiopia is consistent with previous findings from simi-










Inhospital mortality Low GOS (1-4) at discharge Neurologic complications
No dexamethasone Treated with dexamethasone
P < 0.001*
COR = 3.18 (95% CI = 1.90-5.33)
P < 0.001*
COR =2.65 (95%CI = 1.76-3.99)
P = 0.456
Fig. 1 Association between adjuvant dexamethasone treatment and discharge outcomes in patients treated as bacterial meningitis in Ethiopia,
2011–2015. COR – Crude odds ratio, GOS – Glasgow Outcome Score. * Denotes statistical significance
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with proven acute bacterial meningitis was too low to
address this question.
More important, however, this study demonstrated
that dexamethasone treatment seems to be harmful in
patients who were treated as ABM without any CSF find-
ings that supported the diagnosis of ABM or when CSF
was not analysed. One likely explanation for its association
with unfavorable outcome is that, as it has repeatedly been
highlighted in this paper, the majority of the patients likely
suffered from other alternative diagnoses. Dexamethasone
administration to patients with severe brain or systemic
infections without simultaneously treating the underlying
disease condition could have resulted in the poorer
outcomes. As this is the first study that looked at the ef-
fect of dexamethasone in patients treated with only clinic-
ally presumptive diagnosis of ABM, it makes it valuable
for the real situation in developing countries.
However, our study has multiple limitations worth men-
tioning. This is a retrospective study which may be af-
fected by poor documentation and loss of medical
records. Moreover, patients who were given dexametha-
sone might have had severe disease from the outset and,
hence, the poor outcome could be due to their underlying
medical condition rather than the dexamethasone use per
se. Last but not least, the study may not be representative
for the country because it involved mainly teaching hospi-
tals. Nevertheless, it must be assumed that the rate of
treatment of cases with suspected ABM lacking any diag-
nostic workup is even higher throughout the country.
Conclusion
Adjuvant dexamethasone use in management of suspected
but unproven cases of bacterial meningitis in teaching
hospitals in Ethiopia was associated with an increased
mortality and poor discharge GOS. These findings re-
affirm the lack of evidences for its broad use for presumed
meningitis in low income countries and show that there
are potential deleterious effects in unconfirmed cases.
Physicians practising under such circumstances should
abide with the current recommendations and defer the
use of adjuvant corticosteroid in clinically suspected cases
of bacterial meningitis without CSF alterations that sup-
port the diagnosis.
Additional file
Additional file 1: Assessment of treatment strategies for bacterial
meningitis in Ethiopia. The English version of the tool used for data
collection. (PDF 836 kb)
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Table 5 Subgroup analysis for association of dexamethasone
with discharge outcome in patients treated as bacterial
meningitis at teaching hospitals in Ethiopia, 2011–2015
Variables Death Low GOS
OR 95 % CI P OR 95 % CI P
Age
< 50 years 3.08 1.74–5.48 <0.001* 2.83 1.79–4.48 <0.001*
> = 50 years 4.00 1.19–13.46 0.025* 2.68 1.0–7.21 0.051
Duration of illness
< =2 days 4.02 1.37–11.77 0.011* 2.05 0.94–4.50 0.072
> 2 days 2.93 1.62–5.30 <0.000* 2.91 1.79–4.72 <0.001*
Level of conscious
14 and 15 2.21 0.94–5.21 0.070 1.82 0.996 0.051
< 14 3.69 1.84–7.40 <0.001* 388 20.3–7.44 <0.001*
HIV status
Positive 3.25 0.46–22.93 0.237 18.00 1.63–198.51 0.018*
Negative 3.38 1.91–5.66 <0.001* 2.49 1.63–3.80 <0.001*
Prior antibiotics
Yes 3.59 1.24–10.38 0.018* 5.97 2.47–14.44 <0.001*
No 3.04 1.68–5.50 <0.001* 2.07 1.30–3.29 0.002*
Focal neurologic deficit
Yes 3.20 0.67–15.38 0.146 0.80 0.16–3.99 0.789
No 3.00 1.72–5.23 <0.001* 2.77 1.80–4.29 0.003*
CSF appearance
Turbid 2.72 0.67–11.11 0.163 2.44 0.79–7.51 0.121
Clear 6.26 1.95–20.12 0.002* 4.28 2.14–8.58 <0.001*
TB suspected
Yes 3.90 0.45–34.02 0.218 3.46 0.83–14.36 0.087
No 3.09 1.79–5.34 <0.001* 2.18 1.40–3.39 0.001*
Diagnosis of meningitis
Confirmed – 1 1 – 1 1
Probable 2.31 0.68–7.86 0.180 3.22 1.24–8.36 0.016*
Suspected 3.38 1.73–6.59 <0.001* 2.09 1.16–3.75 0.014*
Non-cases 6.98 1.50–32.56 0.013* 3.17 1.41–7.15 0.005*
*Statistically significant
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